“I was a principal investigator in the randomized sham-controlled trial. After 90 days, the unblinded trial data demonstrated results significantly favoring the active therapeutic device. Felix effectively fills the critical therapeutic gap between oral pharmacotherapy and deep brain surgery.”
Professor of Neurology, Weill Cornell Medical School